Study of Navlimetostat BMS-986504 Treatment for Adults With Advanced or Metastatic Non-small Cell Lung Cancer NSCLC Having Homozygous MTAP Deletion After Previous Therapies

What this Trial Is About

Researchers are evaluating the safety and effectiveness of Navlimetostat BMS-986504 as a single treatment in adults with advanced or metastatic Non-small Cell Lung Cancer NSCLC who have a specific genetic change called homozygous MTAP deletion. This study focuses on patients whose cancer has worsened despite previous treatments and aims to better understand how this drug works in this group. Participants will receive Navlimetostat in one of two different dose levels to compare effects. The drug is given as specified doses on certain days, and the study is randomized and open-label, meaning both researchers and participants know which dose is given. There are no placebo groups, and the study follows participants over time to assess responses and safety. During the study, participants will undergo regular assessments including imaging scans to measure tumor response using RECIST v1.1 criteria, evaluations of symptoms and quality of life using specialized questionnaires, and monitoring for side effects and overall survival. These measures will be tracked up to three years after the last dose of the study treatment to gather comprehensive information on the treatments impact and safety profile.

A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)